Overview: NGS Aicardi-Goutieres Sequencing TestIntroduction: The NGS Aicardi-Goutieres Sequencing Test sequences genes to diagnose Aicardi-Goutieres syndrome, causing neurological decline. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Aicardi-Goutieres syndrome (AGS).
Other Names: AGS Assay, Aicardi-Goutieres Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: AGS sequencing began in the 2000s with interferonopathy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose Aicardi-Goutieres syndrome, guides treatment, and evaluates patients with neurological decline.
Test Parameters: 1. Aicardi-Goutieres Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of neurological decline, seizures, or developmental delays.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neurological decline, seizures, calcifications, or family history of AGS. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, AGS implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze AGS genes (e.g., TREX1, RNASEH2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for AGS diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm AGS, guiding supportive care or genetic counseling. Negative results may require broader sequencing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain CT, CSF analysis, or interferon signature testing to confirm AGS diagnosis.
Test Limitations: Not all AGS cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN AGS Guidelines, 2023; Neurology, Crow YJ, 2022.
